12:00 AM
 | 
Jan 16, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

CBP501 regulatory update

FDA granted Orphan Drug designation for CanBas' CBP501 to treat mesothelioma in combination with cisplatin and pemetrexed. CanBas expects...

Read the full 74 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >